Critical Care Management of Pan-Resistant Acinetobacter Osteomyelitis Requiring Novel Antibiotic Therapy

Authors

Nidhi Navaratana, Oakland University William Beaumont School of Medicine Medical Student
Patrick D. Thrasher, Corewell Health East Resident
Nasim Shakibai, Corewell Health East Resident
Roy Soto, Corewell Health East

Document Type

Conference Proceeding

Publication Date

10-12-2025

Abstract

A 65-year-old male with diabetes and chronic left heel osteomyelitis developed sepsis from pan-resistant Acinetobacter baumannii requiring emergent free flap surgery and initiation of sulbactam-durlobactam (Xacduro), a novel, rarely used antibiotic. His course was complicated by acute encephalopathy likely secondary to sepsis. Due to the high cost, IV-only administration, and Q6H dosing of sulbactam-durlobactam, discharge planning was complex, necessitating LTACH placement. This case highlights challenges in perioperative management, antimicrobial stewardship, and post-ICU transitions for patients requiring emerging antimicrobials.

Comments

American Society of Anesthesiologists, The Anesthesiology Meeting, October 10-14, 2025, San Antonio, TX

Recommended Citation

Navartana N, Thrasher PD, Shakibai N, Soto R. Critical care management of pan-resistant Acinetobacter osteomyelitis requiring novel antibiotic therapy. Presented at: American Society of Anesthesiologists, The Anesthesiology Meeting; 2025 Oct 12; San Antonio, TX. Available from:https://www.abstractsonline.com/pp8/#!/21028/presentation/8700